Study the Effect of chemical treatments on the physiological and biochemical parameters of patients with cancerous diseases in Thi-Qar Governorate
Main Article Content
Keywords
Cancerous disease, chemical treatments
Abstract
This research was designed to study the impact of chemotherapy on cancer patients' physiological and biochemical alterations in Thi-Qar Governorate. The study included 138 participants and 46 women with breast cancer divided into 23 samples taken (1-5 doses) and 23 took more than 5 doses The treatment was Paclitaxel and Carboplatin., and 46 males with liver cancer divided into 23 samples taken (1-5 doses) and 23 took more than 5 doses The treatment was Doxorubicin. 46 healthy individuals, 23 males and 23 females. The study was conducted in Al-Haboubi Hospital, Department of Oncology, in Thi-Qar Governorate, for the period between December 2022 - February 2023. With regard to blood parameters, the results showed a clear decrease in hemoglobin, red blood cells, white blood cells, and platelets in males and females who were treated with chemotherapy. As for liver enzymes, we notice an increase in ALT and AST in males with liver cancer more than in females with breast cancer. As for the ALP enzyme, we notice an increase in both sexes, and there is no significant difference between them. As for lipid , it is noted that there are clear changes, an increase in cholesterol and TG, a decrease in HDL in both sexes. For the hormones that are LH and E2, we notice a clear decrease in the value of the hormones compared to the normal level. For males, we notice a clear decrease in FSH and testosterone compared to the normal level.
References
1. Wong, M.C.S.; Huang, J.; Lok, V.; Wang, J.; Fung, F.; Ding, H.; Zheng, Z.J. Differences in Incidence and Mortality Trends of Colorectal
Cancer Worldwide Based on Sex, Age, and Anatomic Location. Clin. Gastroenterol. Hepatol. 2020.
2. ursons, J. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol. Res. 7, 1162–1174 (2019).
3. Tashima, T.: Possibilities of Cancer Chemotherapy Based on Transporter-Conscious Drug Design, Journals of Carcinogenesis & Mutagenesis, 2016, Vol(6), No(4), pp.: 2157-2518.
4. Generaal, J.D., Lansdorp, C.A., Boonstra, O., van Leeuwen, B.L.,Vanhauten, H.A.M., Stevenson, M.G., Been, L.B.Hyperbaric oxygen therapy for radiation-induced tissue injury following sarcoma treatment: A retrospective analysis of a Dutch cohort (2020) PLoS ONE, 15 (6), art. no. e0234419.
5. Szok D, Tajti J, Nyári A, Vécsei L. Therapeutic approaches for peripheral and central neuropathic pain. Behav Neurol. 2019;2019:8685954.
6. Allain C. C. et al., Clin. Chem. (1974), 20/4, p.470-475.
7. Fossati P., Prencipe L., Clin. Chem. (1982), 28, p.2077-2080.
8. A colorimetric method for the determination of serum GOT and GPT, REITMAN S. and FRANKEL S., Amer. J. Clin. Path., 1957; 28, p.56-63.
9. Kind P. R. N., King E. J, Estimation of plasma Phosphatase by determination of hydrolysed phenol with amino-anti-antipyrine, J. Clin. Path, 7,(1954), p.322-326
10. Incekol, D. and murray,C. (2011): Managing Side Effects Chemotherapy, J.
11. Recchia,F.;Candeloro,G;Necozione,S.;Accorsi,P.;Recchia,C.O.;Tombolin i, V. and Rea, S.(2010):Prolonged disease control after myeloablative chemotherapy ,autologous transplantation and immunotherapy in high- risk early breast cancer, J. Anticancer research 30:209-216.
12. Salem,H.; Eissa,L.; Ahmed,M. R.; EL-helw, M.; and EL-Gayar,A.(2006) Original articleevalution of some biochemical markers as prognostic factors in malignant lymphomas, J. Pak. J. Pharm. Sci. 19(3): 219-230.
13. Zhang,Y.; Chen , J.; Liang ,D.; Yuan ,Y.; Xiaoting W. (2008): Effects of Human Growth Hormone on Haematopoietic Recovery of Rats Receiving Chemotherapy, J. Chemotherapy 54:447–455.
14. Oludiran, O.; Egwakhide, E.; Elusoji ,C.; Oluedo, A.( 2008): Haemorheological Changes in African Breast Cancer Patients, J. African Journal of Reproductive Health 12 (1) :84-89.
15. Rao,C.R.(2010): Biophysocal investigation on blood of cancer patients.PhD.Thesis , University of Hyderabad, India .
16. Hassan, F. M. and Weeda, E. A. (2010):Anemia in Elderly Sudanese Lung Cancer Patients Treated with Chemotherapy, j. The Open Lung Cancer Journal 3: 34-37.
17. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54–63.
18. Limdi, J.K. and Hyde, G.M. (2003). Evaluation of abnormal liver function tests. Postgrad Med. J. 79: 307-312.
19. Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol. 2015;38:142–147. doi: 10.1177/0192623309351719.
20. Murad, Taha. (2005). Some physiological and immunological effects of Tamoxifen in breast cancer patients and female white rat (Rattus norvegicus), University of Baghdad, Baghdad.
21. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study: Rationale, design, and conduct. Drug Safety. 2014;32:55–68. doi: 10.2165/00002018-200932010-00005.
22. Hoofnagle JH, Björnsson ES (2019) Drug-induced liver injury-types and phenotypes. New England Journal of Medicine 381: 264-273.
23. MirenGarcía-Cortés, Aida Ortega-Alonso, M Isabel Lucena, Raúl J Andrade (2018) Drug-induced liver injury: a safety review, Expert Opinion on Drug Safety.
24. Bernal W, Lee WM, Wendon J, Fin Stolze Larsen, Roger Williams (2017) Acute liver failure: a curable disease by2024? J Hepatol 62: S112-120.
25. Journal of the American College of Cardiology (2013): "2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults."
26. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, Fung K, Anderson GM. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiol. 2017;2(1):88–93.
27. Xu J, Qiu X, Li Y, Sun N, Zhang Y, Shu J. Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population. Medicine (Baltimore). 2020;99(38):e22037.
28. Lu Y, Wang P, Lan N, Kong F, Abdumijit A, Tu S, Li Y, Yuan W. Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol. 2022;12:899335.Article PubMed PubMed Central Google Scholar
29. Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM, et al. Chemotherapy agents alter plasma lipids in cancer patients and show differential effects on lipid metabolism genes in liver cells. PLoS ONE. (2016) 11:e0148049. doi: 10.1371/journal.pone.0148049
30. Giok S. Liem, Frankie K. F. Mo, Elizabeth Pang, Joyce J. S. Suen, Nelson L. S. Tang, Kun M. Lee, Claudia H. W. Yip, Wing H. Tam, 3 Rita Ng, 1 Jane Koh, Christopher C. H. Yip, Grace W. S. Kong, and Winnie Yeo , hemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles.2015; Published online 2015 Oct 20. doi: 10.1371/journal.pone.0140842.
31. Vishwakarma G, Ndetan H, Das DN, Gupta G, Suryavanshi M, Mehta A, Singh KP. Reproductive factors and breast cancer risk: A meta-analysis of case-control studies in Indian women. South Asian J Cancer. 2019 Apr-Jun;8(2):80-84.
32. Dayalu Naik, S. L , S. Hedau, A.K. Bahadur, R. Saha, S. Kaur and A. Ray,, (2008),. SEX HORMONE BINDING GLOBULIN IN BREAST CANCER,, 13. Indian Journal of Clinical Biochemistry, 2008 / 23 (3) 250-254
33. Ghada N. Farhat, Steven R. Cummings, Rowan T. Chlebowski, Neeta Parimi, Jane A. Cauley, Thomas E. Rohan, Alison J. Huang, Mara Vitolins, F. Allan Hubbell, JoAnn E. Manson, Barbara B. Cochrane, Dorothy S. Lane and Jennifer S. Lee ,(2011) , SexHormone Levels and Risks of Estrogen Receptor–Negative and Estrogen Receptor–Positive Breast Cancers , JNCI J Natl Cancer Inst 103(7): 525 doi:10.1093/jnci/djr116. Oxford University Press.
34. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, et al. Hypothalamic- Pituitary and Growth Disorders in Survivors of Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(8):2761–84. Epub 2018/07/10. 29982476.
35. Gebauer J, Higham C, Langer T, Denzer C, Brabant G. Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review. Endocr Rev. 2019;40(3):711–67. Epub 2018/11/27. pmid:30476004.
Cancer Worldwide Based on Sex, Age, and Anatomic Location. Clin. Gastroenterol. Hepatol. 2020.
2. ursons, J. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol. Res. 7, 1162–1174 (2019).
3. Tashima, T.: Possibilities of Cancer Chemotherapy Based on Transporter-Conscious Drug Design, Journals of Carcinogenesis & Mutagenesis, 2016, Vol(6), No(4), pp.: 2157-2518.
4. Generaal, J.D., Lansdorp, C.A., Boonstra, O., van Leeuwen, B.L.,Vanhauten, H.A.M., Stevenson, M.G., Been, L.B.Hyperbaric oxygen therapy for radiation-induced tissue injury following sarcoma treatment: A retrospective analysis of a Dutch cohort (2020) PLoS ONE, 15 (6), art. no. e0234419.
5. Szok D, Tajti J, Nyári A, Vécsei L. Therapeutic approaches for peripheral and central neuropathic pain. Behav Neurol. 2019;2019:8685954.
6. Allain C. C. et al., Clin. Chem. (1974), 20/4, p.470-475.
7. Fossati P., Prencipe L., Clin. Chem. (1982), 28, p.2077-2080.
8. A colorimetric method for the determination of serum GOT and GPT, REITMAN S. and FRANKEL S., Amer. J. Clin. Path., 1957; 28, p.56-63.
9. Kind P. R. N., King E. J, Estimation of plasma Phosphatase by determination of hydrolysed phenol with amino-anti-antipyrine, J. Clin. Path, 7,(1954), p.322-326
10. Incekol, D. and murray,C. (2011): Managing Side Effects Chemotherapy, J.
11. Recchia,F.;Candeloro,G;Necozione,S.;Accorsi,P.;Recchia,C.O.;Tombolin i, V. and Rea, S.(2010):Prolonged disease control after myeloablative chemotherapy ,autologous transplantation and immunotherapy in high- risk early breast cancer, J. Anticancer research 30:209-216.
12. Salem,H.; Eissa,L.; Ahmed,M. R.; EL-helw, M.; and EL-Gayar,A.(2006) Original articleevalution of some biochemical markers as prognostic factors in malignant lymphomas, J. Pak. J. Pharm. Sci. 19(3): 219-230.
13. Zhang,Y.; Chen , J.; Liang ,D.; Yuan ,Y.; Xiaoting W. (2008): Effects of Human Growth Hormone on Haematopoietic Recovery of Rats Receiving Chemotherapy, J. Chemotherapy 54:447–455.
14. Oludiran, O.; Egwakhide, E.; Elusoji ,C.; Oluedo, A.( 2008): Haemorheological Changes in African Breast Cancer Patients, J. African Journal of Reproductive Health 12 (1) :84-89.
15. Rao,C.R.(2010): Biophysocal investigation on blood of cancer patients.PhD.Thesis , University of Hyderabad, India .
16. Hassan, F. M. and Weeda, E. A. (2010):Anemia in Elderly Sudanese Lung Cancer Patients Treated with Chemotherapy, j. The Open Lung Cancer Journal 3: 34-37.
17. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54–63.
18. Limdi, J.K. and Hyde, G.M. (2003). Evaluation of abnormal liver function tests. Postgrad Med. J. 79: 307-312.
19. Senior JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol. 2015;38:142–147. doi: 10.1177/0192623309351719.
20. Murad, Taha. (2005). Some physiological and immunological effects of Tamoxifen in breast cancer patients and female white rat (Rattus norvegicus), University of Baghdad, Baghdad.
21. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study: Rationale, design, and conduct. Drug Safety. 2014;32:55–68. doi: 10.2165/00002018-200932010-00005.
22. Hoofnagle JH, Björnsson ES (2019) Drug-induced liver injury-types and phenotypes. New England Journal of Medicine 381: 264-273.
23. MirenGarcía-Cortés, Aida Ortega-Alonso, M Isabel Lucena, Raúl J Andrade (2018) Drug-induced liver injury: a safety review, Expert Opinion on Drug Safety.
24. Bernal W, Lee WM, Wendon J, Fin Stolze Larsen, Roger Williams (2017) Acute liver failure: a curable disease by2024? J Hepatol 62: S112-120.
25. Journal of the American College of Cardiology (2013): "2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults."
26. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, Fung K, Anderson GM. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiol. 2017;2(1):88–93.
27. Xu J, Qiu X, Li Y, Sun N, Zhang Y, Shu J. Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population. Medicine (Baltimore). 2020;99(38):e22037.
28. Lu Y, Wang P, Lan N, Kong F, Abdumijit A, Tu S, Li Y, Yuan W. Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol. 2022;12:899335.Article PubMed PubMed Central Google Scholar
29. Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM, et al. Chemotherapy agents alter plasma lipids in cancer patients and show differential effects on lipid metabolism genes in liver cells. PLoS ONE. (2016) 11:e0148049. doi: 10.1371/journal.pone.0148049
30. Giok S. Liem, Frankie K. F. Mo, Elizabeth Pang, Joyce J. S. Suen, Nelson L. S. Tang, Kun M. Lee, Claudia H. W. Yip, Wing H. Tam, 3 Rita Ng, 1 Jane Koh, Christopher C. H. Yip, Grace W. S. Kong, and Winnie Yeo , hemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles.2015; Published online 2015 Oct 20. doi: 10.1371/journal.pone.0140842.
31. Vishwakarma G, Ndetan H, Das DN, Gupta G, Suryavanshi M, Mehta A, Singh KP. Reproductive factors and breast cancer risk: A meta-analysis of case-control studies in Indian women. South Asian J Cancer. 2019 Apr-Jun;8(2):80-84.
32. Dayalu Naik, S. L , S. Hedau, A.K. Bahadur, R. Saha, S. Kaur and A. Ray,, (2008),. SEX HORMONE BINDING GLOBULIN IN BREAST CANCER,, 13. Indian Journal of Clinical Biochemistry, 2008 / 23 (3) 250-254
33. Ghada N. Farhat, Steven R. Cummings, Rowan T. Chlebowski, Neeta Parimi, Jane A. Cauley, Thomas E. Rohan, Alison J. Huang, Mara Vitolins, F. Allan Hubbell, JoAnn E. Manson, Barbara B. Cochrane, Dorothy S. Lane and Jennifer S. Lee ,(2011) , SexHormone Levels and Risks of Estrogen Receptor–Negative and Estrogen Receptor–Positive Breast Cancers , JNCI J Natl Cancer Inst 103(7): 525 doi:10.1093/jnci/djr116. Oxford University Press.
34. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, et al. Hypothalamic- Pituitary and Growth Disorders in Survivors of Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(8):2761–84. Epub 2018/07/10. 29982476.
35. Gebauer J, Higham C, Langer T, Denzer C, Brabant G. Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review. Endocr Rev. 2019;40(3):711–67. Epub 2018/11/27. pmid:30476004.
Article Sidebar
Published
May 17, 2023
Article Details
How to Cite
Ghada Majeed Lafah, & Mohannad Abdulrazzaq Gati. (2023). Study the Effect of chemical treatments on the physiological and biochemical parameters of patients with cancerous diseases in Thi-Qar Governorate. Journal of Population Therapeutics and Clinical Pharmacology, 30(11), 364–374. https://doi.org/10.47750/jptcp.2023.30.11.037
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.